Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO02059084 A2 2002-08-01 [WO200259084]WO02059084 A3 2003-10-16 [WO200259084] / 2002-08-012003-10-16
申请号/申请日
2002WO-US00371 / 2002-01-04
发明人
SAUVE ANTHONY A;SCHRAMM VERN L;
申请人
ALBERT EINSTEIN COLLEGE OF MEDICINE;
主分类号
IPC分类号
C07D-307/20C07D-405/04C07H-019/04C07H-019/10C07H-019/20
摘要
(WO200259084) The present invention provides pharmaceutical compositions for inhibiting and treating diseases associated with ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2001US-60259720 2001-01-04
主权利要求
(WO200259084) What is claimed is: A compound represented by the formula: wherein A is a nitrogen- , oxygen- , or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon- , nitrogen- , or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon- , nitrogen- , or sulfur-substituted pyrophosphodiester bridge. 2. The compound of Claim 1, wherein A is an N-linked aryl or heterocyclic group. 3. The compound of Claim 2, wherein A is a nicotinamide group, a pyridyl group, a substituted pyridyl group, a pyrimidyl group, or a substituted pyrimidyl group. 4. The compound of Claim 3, which is a nicotinamide 2'- deoxyriboside. 5. The compound of Claim 3, which is β-l'-nicotinamide-2'- deoxyribose, β-D-l'-nicotinamide-2'-deoxyribofuranoside, β-l'-pyridyl-2'- deoxyribose, or 5'-phospho-l'-pyridyl-deoxyribose. 6. The compound of Claim 1, wherein A is an O-linked aryl or heterocyclic group having the formula -O-Y, wherein Y is an aryl or heterocyclic group. 7. The compound of Claim 6, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group. 8. The compound of Claim 1, wherein A is an S-linked aryl or heterocyclic group having the formula -S-Y, wherein Y is an aryl or heterocyclic group. 9. The compound of Claim 8, wherein the aryl or heterocyclic group is a phenyl group, a substituted phenyl group, a pyridyl group, a substituted pyridyl group, or a pyrimidyl group. 10. The compound of Claim 1, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 11. The compound of Claim 2, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 12. The compound of Claim 6, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 13. The compound of Claim 8, wherein both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen. 14. The compound of Claim 1, wherein D is a primary alcohol or hydrogen. 15. The compound of Claim 2, wherein D is a primary alcohol or hydrogen. 16. The compound of Claim 6, wherein D is a primary alcohol or hydrogen. 17. The compound of Claim 8, wherein D is a primary alcohol or hydrogen. 18. A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically-acceptable carrier. 19. A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically-acceptable carrier. 20. A pharmaceutical composition comprising the compound of Claim 6 and a pharmaceutically-acceptable carrier. 21. A pharmaceutical composition comprising the compound of Claim 8 and a pharmaceutically-acceptable carrier. 22. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 1 effective to inhibit the enzyme. 23. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 2 effective to inhibit the enzyme. 24. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 6 effective to inhibit the enzyme. 25. A method for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme, comprising contacting the enzyme with an amount of the compound of Claim 8 effective to inhibit the enzyme. 26. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 1 in an amount effective to treat the disease or condition. 27. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 2 in an amount effective to treat the disease or condition. 28. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 6 in an amount effective to treat the disease or condition. 29. A method for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, or ADP-ribosyl hydrolase enzyme in a subject in need of treatment thereof, comprising administering to the subject the compound of Claim 8 in an amount effective to treat the disease or condition.
法律状态
(WO200259084) LEGAL DETAILS FOR WO02059084  Actual or expected expiration date=2004-07-04    Legal state=DEAD    Status=LAPSED     Event publication date=2002-01-04  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS0200371  Application date=2002-01-04  Standardized application number=2002WO-US00371     Event publication date=2002-08-01  Event code=WO/A2  Event type=Examination events  International application published without international search report  Publication country=WO  Publication number=WO02059084  Publication stage Code=A2  Publication date=2002-08-01  Standardized publication number=WO200259084     Event publication date=2002-08-01  Event code=WO/AK  Event indicator=Pos  Event type=Designated states  Designated states AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW    Event publication date=2002-08-01  Event code=WO/AL  Event indicator=Pos  Event type=Designated states  Designated countries for regional patents GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG    Event publication date=2003-05-22  Event code=WO/DFPE  Event type=Examination events  Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)    Event publication date=2003-10-16  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO02059084  Publication stage Code=A3  Publication date=2003-10-16  Standardized publication number=WO200259084     Event publication date=2004-07-04  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU2002246956  Actual or expected expiration date=2014-07-31    Legal state=DEAD    Status=EXPIRED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2002246956  Application date in the designated or member state=2002-01-04   Application number in the designated or member state=2002AU-0246956 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2002246956  Publication stage code in the designated or member state=B2  Publication date in the designated or member state=2006-11-02   Publication number in the designated or member state=AU2002246956    Event publication date=2003-07-23  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=AU     Event publication date=2014-07-31  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE BG  Actual or expected expiration date=2022-01-04    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=BG Corresponding appl: BG10801702    Event publication date=2003-07-22  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=BG  LEGAL DETAILS FOR DESIGNATED STATE CA2433840  Actual or expected expiration date=2015-01-05    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2433840  Application date in the designated or member state=2002-01-04   Application number in the designated or member state=2002CA-2433840 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2433840  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2002-08-01   Publication number in the designated or member state=CA2433840    Event publication date=2003-07-03  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CA     Event publication date=2015-02-16  Event code=CA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2003-11-13    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2003-11-13  Event code=WO/REG  Event code=DE/8642  Event indicator=Neg  Event type=Non-entry into national phase  Event type=Event indicating Not In Force  Reference to a national code Impact abolished for de - i.e. PCT appl. not ent. German phase Wirkung weggefallen fuer de Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP1370139  Actual or expected expiration date=2014-08-22    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=EP Corresponding appl: EP02714706  Application date in the designated or member state=2002-01-04   Application number in the designated or member state=2002EP-0714706 Corresponding cc:  Designated or member state=EP Corresponding pat: EP1370139  Publication stage code in the designated or member state=A2  Publication date in the designated or member state=2003-12-17   Publication number in the designated or member state=EP1370139    Event publication date=2002-09-25  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2003-07-18  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=EP     Event publication date=2003-12-17  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=EP     Event publication date=2015-02-11  Event code=EP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE JP  Actual or expected expiration date=2006-03-27    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=JP     Event publication date=2006-03-27  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=JP     Event publication date=2006-03-27  Event code=WO/WWW  Event indicator=Neg  Event type=Event indicating Not In Force  Wipo information: withdrawn in national office Corresponding cc:  Designated or member state=JP
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部